Peripheral blood stem cell (PBSC) graft is widely used for allogeneic transplantation and produces faster neutrophil recovery than bone marrow cells. Although the mobilization of peripheral blood stem cells from normal donors using filgrastim is widely used, the ideal schedule for the administration of filgrastim has not been determined.
To compare the efficacy of peripheral blood stem cell mobilization on day 5 of filgrastim between once-daily(1∗10 mcg/kg) and twice-daily(2∗5 mcg/kg) administration, we performed a prospective study on our healthy donors.
Healthy allogeneic donors whose PBSC mobilisation were done at Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Stem Cell Transplantation Unit, were separated to once-daily(1∗10 mcg/kg) and twice-daily(2∗5 mcg/kg) administration groups. 40 donors were randomly assigned to once-daily and twice-daily groups.
The number of CD34 cells collected on day 5 was not significantly different (9.6 ∗ 106 cells/kg in once-daily group and 9.1 ∗ 106 cells/kg in twice-daily group, P:0.620). The baseline white blood cell count,donor age and sex did not significantly affect the CD34 cell yield.
Once-daily administration of filgrastim (1∗10 mcg/kg) appeared to be appropriate for the mobilization of CD34 cells in normal donors.